Quarterly report pursuant to Section 13 or 15(d)

Disclosure of Correction of Immaterial Error

v3.21.2
Disclosure of Correction of Immaterial Error
3 Months Ended
Sep. 30, 2021
Disclosure of Correction of Immaterial Error [Abstract]  
Disclosure of Correction of Immaterial Error

24. Disclosure of Correction of Immaterial Error

The Company reclassified certain expenses on its Condensed Consolidated Statement of Operations effective for the first quarter of Fiscal 2021.  These changes in classification align the Company’s external presentation of operating-related expenses with the way that the Company's chief operating decision maker (CODM) expects to assess spend and resource allocation decisions around the Company’s operations as well as provide users of the financial statements with more information including separately stating cost of goods sold and classifying costs on the Statement of Operations according to their primary function (e.g. Research and development). The Company has reclassified these expenses for the prior period presented to provide comparable historical financial information. The Company intends to use this new presentation of operating-related expenses going forward.

The Company assessed the materiality of this error in accordance with SAB No. 99 Materiality and Accounting Standards Codification 250, Accounting Changes and Error Corrections and determined that this was an immaterial error.

The reclassifications did not have any impact to consolidated operating income (loss), net income (loss), cash flows or earnings per share. The following tables illustrate the reclassifications and financial impact on the various line items impacted on the Condensed Consolidated Statement of Operations and Segment Reporting, as follows:

Statement of Operations Reclassifications

    

Three Months Ended

(In thousands)

September 30, 2020

Operating expense:

As Reported

    

Adjustment

    

As Revised

% Change

Cost of goods sold

$

 

$

107

 

$

107

100

%

Research and development

 

1,762

 

 

100

 

 

1,862

 

6

%

General and administrative

5,572

(207)

5,365

(4)

%

Total operating expenses

$

7,334

$

7,334

Segment Reporting Reclassifications

As Reported:

For the Three Months Ended September 30, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Eliminations

Total

Cost of goods sold

$

$

$

$

Research and development

342

1,638

(218)

1,762

General and administrative

2,672

3,130

(230)

5,572

As Revised:

For the Three Months Ended September 30, 2020 (in thousands)

iBio, Inc.

iBio CDMO

Eliminations

Total

Cost of goods sold

$

54

$

53

$

$

107

Research and development

235

1,845

(218)

1,862

General and administrative

2,672

2,923

(230)

5,365